• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

Medical News Interviews

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

No Use Of Hydroxyurea In Country With Most Sickle Cell Anemia

1
  • by alexperjescuadmin
  • in Public Health
  • — 9 Dec, 2007
No Use Of Hydroxyurea In Country With Most Sickle Cell Anemia
AudioMedica News
No Use Of Hydroxyurea In Country With Most Sickle Cell Anemia
No Use Of Hydroxyurea In Country With Most Sickle Cell Anemia
00:00 /
RSS Feed
Share
Link
Embed
Zakari Aliyu
Zakari Aliyu

REFERENCE: American Society of Hematology Annual Meeting, December 8-11 2007, Atlanta
ZAKARI ALIYU, Howard University, Washington DC
Nigeria has the highest incidence of sickle cell anemia in the world, with over 150,000 children being born each year with the disease. But a new study has shown that no one is using the standard therapy hydroxyurea to treat it. Derek Thorne got more from Zakari Aliyu of Howard University in Washington DC.

[audio:https://www.audiomedica.com/podcasting/global_health/071208_zakari_aliyu.mp3]
Share

Tags: cellchildrendiseasehematologicNewspodcastpodcastingstudytherapiestherapy

You may also like...

  • Jennifer Smith Global Map Of Trachoma Distribution: Significant Step For Preventing Blindness 1 Dec, 2010
  • Audio Journal of Infectious Disease: Reporting from the 2006 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, San Francisco Audio Journal of Infectious Disease: Reporting from the 2006 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, San Francisco 29 Sep, 2006
  • Chia Kee Seng Singapore and London researchers collaborate on public health 24 Sep, 2012
  • Millennium Health Goals Threatened By Chronic Diseases In Poor Countries Millennium Health Goals Threatened By Chronic Diseases In Poor Countries 17 Apr, 2010

1 Comment

  1. Lisa Ahramjian says:
    January 8, 2008 at 9:03 pm

    NIH Consensus Development Conference:
    Hydroxyurea Treatment for Sickle Cell Disease
    February 25–27, 2008

    Register Online Now!

    In order to take a closer look at this important topic, the National Heart, Lung, and Blood Institute and the Office of Medical Applications of Research of the National Institutes of Health will convene a Consensus Development Conference from February 25–27, 2008, to assess the available scientific evidence related to the following questions:

    What is the efficacy (results from clinical studies) of hydroxyurea treatment for patients who have sickle cell disease in three groups: infants, preadolescents, and adolescents/adults?

    What is the effectiveness (in everyday practice) of hydroxyurea treatment for patients who have sickle cell disease?

    What are the short- and long-term harms of hydroxyurea treatment?

    What are the barriers to hydroxyurea treatment for patients who have sickle cell disease and what are the potential solutions?

    What are the future research needs?

    Additional information is available at http://consensus.nih.gov/2008/2008SickleCellCDC119main.htm

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

  • Previous story Large Risk Reduction For Rivaroxaban In Blood Clot Prevention
  • Next story New Drug AMG 531 Effective in Splenectomized Patients with Chronic Immune Thrombocytopenic Purpura
  • News

    • Mandeep Mehra MDCOVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
    • Ultrahypofractionated Radiation Just As Effective for Prostate CancerUltrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
  • Related interviews

    • Microbiome Diversity Key To Survival After…
    • Ibrutinib: New Frontline Standard for Chronic…
    • Genomic-led AML Clinical Decision Making Within Seven Days
    • New Front Line Standard for Older Patients with…
    • Which Tasks Most Influence Pediatric PT…
  • Home
  • Public Health
  • No Use Of Hydroxyurea In Country With Most Sickle Cell Anemia

© Copyright 2021 AudioMedica.com. Typegrid Theme by WPBandit.